We summarize various targeted degradation strategies and their respective advantages and disadvantages, hoping to provide guidance value for the development of targeted protein degradation drugs.
Summary of PROTAC Degraders in Clinical Trials.pdfDoriaFang
A major class of molecules that may enable such proteins to be modulated through TPD are known as proteolysis-targeting chimera (PROTAC) protein degraders. Here we talk about the summary of PROTAC degraders in clinical trials.
PROTAC Technology in Tumor Targeted Therapy - Creative BiolabsCreative-Biolabs
Today, we will explore the protac technology applied in tumor-targeted therapy. The following will be presented to you, such as a brief introduction to Protac, the mechanism of action, the advantages and disadvantages of protac as a drug, and the core content: the application of protac technology in tumor therapy. And the last part, the protac solutions provided by Creative Biolabs. If you have any questions about the PROCT development, please email us.
Email: info@creative-biolabs.com
PROTAC Technology: An Effective Targeted Protein Degrader.pdfDoriaFang
PROTACs are heterofunctional small molecules consisting of two ligands linked by an appropriate linker: one ligand recruits and binds the protein of interest (POI), while the other recruits and binds the E3 ubiquitin ligase.
With the passage of time, PROTACs technology has entered an unprecedented stage of development in recent years. According to the different requirements of customers, BOC Sciences can design, synthesize, optimize PROTAC molecules, establish analytical methods and carry out the biological evaluation. Please visit https://protac.bocsci.com for more information.
With the passage of time, PROTACs technology has entered an unprecedented stage of development in recent years. Scientists gradually see the absolute advantages of this technology, which can not only transform non-drug target (undruggable) into feasible drug target (druggable) but also resolve the problem of drug resistance of existing targets. In recent years, we have made great efforts to develop the (PROTAC) platform of protein degradation technology to provide research tools for small molecules targeting so-called non-proprietary drugs, in order to better help customers and help customers in the process of new drug research and development. According to the different requirements of customers, BOC Sciences can design, synthesize, optimize PROTAC molecules, establish analytical methods and carry out the biological evaluation.
12 Types of Targeted Protein Degradation Technologies.pdfDoriaFang
In this article, we list the targeted protein degradation technologies that have made important research progress in recent years, mainly including mechanism of action, representative companies, global R&D status, etc.
Summary of PROTAC Degraders in Clinical Trials.pdfDoriaFang
A major class of molecules that may enable such proteins to be modulated through TPD are known as proteolysis-targeting chimera (PROTAC) protein degraders. Here we talk about the summary of PROTAC degraders in clinical trials.
PROTAC Technology in Tumor Targeted Therapy - Creative BiolabsCreative-Biolabs
Today, we will explore the protac technology applied in tumor-targeted therapy. The following will be presented to you, such as a brief introduction to Protac, the mechanism of action, the advantages and disadvantages of protac as a drug, and the core content: the application of protac technology in tumor therapy. And the last part, the protac solutions provided by Creative Biolabs. If you have any questions about the PROCT development, please email us.
Email: info@creative-biolabs.com
PROTAC Technology: An Effective Targeted Protein Degrader.pdfDoriaFang
PROTACs are heterofunctional small molecules consisting of two ligands linked by an appropriate linker: one ligand recruits and binds the protein of interest (POI), while the other recruits and binds the E3 ubiquitin ligase.
With the passage of time, PROTACs technology has entered an unprecedented stage of development in recent years. According to the different requirements of customers, BOC Sciences can design, synthesize, optimize PROTAC molecules, establish analytical methods and carry out the biological evaluation. Please visit https://protac.bocsci.com for more information.
With the passage of time, PROTACs technology has entered an unprecedented stage of development in recent years. Scientists gradually see the absolute advantages of this technology, which can not only transform non-drug target (undruggable) into feasible drug target (druggable) but also resolve the problem of drug resistance of existing targets. In recent years, we have made great efforts to develop the (PROTAC) platform of protein degradation technology to provide research tools for small molecules targeting so-called non-proprietary drugs, in order to better help customers and help customers in the process of new drug research and development. According to the different requirements of customers, BOC Sciences can design, synthesize, optimize PROTAC molecules, establish analytical methods and carry out the biological evaluation.
12 Types of Targeted Protein Degradation Technologies.pdfDoriaFang
In this article, we list the targeted protein degradation technologies that have made important research progress in recent years, mainly including mechanism of action, representative companies, global R&D status, etc.
Target Validation
Introduction,Drug discovery, Target identification and validation, Target validation and techniques
By
Ms. B. Mary Vishali
Department of Pharmacology
Prota cs and targeted protein degradationDoriaFang
PROTACs (proteolysis targeting chimera) induced targeted protein degradation has emerged as a novel therapeutic strategy in drug development and attracted the favor of academic institutions, large pharmaceutical enterprises, and biotechnology companies. PROTACs opened a new chapter for novel drug development.
Summary of Targeted Protein Degradation in Clinical Trials.pdfDoriaFang
Summary of targeted protein degradation, such as PROTAC and molecular glues in clinical trials. PROTAC and molecular glues are the two main modes of TPD technology based on the UPS.
Target Validation
Introduction,Drug discovery, Target identification and validation, Target validation and techniques
By
Ms. B. Mary Vishali
Department of Pharmacology
Prota cs and targeted protein degradationDoriaFang
PROTACs (proteolysis targeting chimera) induced targeted protein degradation has emerged as a novel therapeutic strategy in drug development and attracted the favor of academic institutions, large pharmaceutical enterprises, and biotechnology companies. PROTACs opened a new chapter for novel drug development.
Summary of Targeted Protein Degradation in Clinical Trials.pdfDoriaFang
Summary of targeted protein degradation, such as PROTAC and molecular glues in clinical trials. PROTAC and molecular glues are the two main modes of TPD technology based on the UPS.
Several Types of PROTACs Based On Nucleic AcidsDoriaFang
So far, more than 10 nucleic acid drugs have been approved for marketing worldwide, and many nucleic acid drugs are in the stage of clinical trials. Nucleic acid drugs are expected to become the third type of drugs after small molecule drugs and antibody drugs.
PROTAC Delivery System Recent Research Advances.pdfDoriaFang
The combination of PROTAC and multifunctional delivery systems will open up new research directions in the field of TPD. Here we will introduce the combination of PROTAC and multifunctional delivery systems.
Future Perspective of PROTAC Combined With CRISPR In Anti-ancer Area.pdfDoriaFang
This article reviews the current status and future of using PROTAC therapy to target epigenetic targets. The article stated that the combination of CRISPR screening and PROTAC technology provides a powerful tool for the development of protein degradation therapies targeting epigenetic targets.
In recent years, the approval of nucleic acid therapeutics for listing has been accelerating. Numerous nucleic acid therapeutics that have the potential to become blockbuster drugs have released clinical data covering cardiovascular and metabolic diseases, liver diseases, and a variety of rare diseases. Especially after the approval of the two mRNA COVID-19 vaccines, nucleic acid therapeutics have received more and more attention from the world.
Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...EduConnections
Therapeutic potential of RNA-targeted antisense oligonucleotides, aptamers, and DNA-targeted triple helix agents. Speech by Dr Michael L Riordan, the founder and CEO of Gilead Sciences at the International Conference on Nucleic Acid Therapeutics sponsored by the National Cancer Institute. 1991.
Antibody drug conjugates (ADCs) are undoubtedly one of the hottest research areas in recent years. To date, there are 15 approved ADCs in the world, of which 13 have been approved by the FDA, one in China (Disitamab Vedotin) and one in Japan (Akalux).
Covalent PROTACs, An Emerging Protein Degradation Technology.pdfDoriaFang
A new technology that combines covalent inhibitors and PROTACs has emerged—covalent PROTAC technology, including reversible covalent and irreversible covalent PROTACs.
Similar to HER2, Trop-2 is a new hot target for research. Trodelvy has been one of the products receiving much attention in recent years, and Dato-DXd from AstraZeneca/Daiichi Sankyo is also advancing rapidly.
Peptide drug conjugates (pd cs) new generation of targeted cancer treatmentDoriaFang
As a new generation of targeted cancer treatment, the well-designed PDC not only retains the advantages of traditional drug delivery, but also increases the penetration of tumor drugs and reduces the toxicity to liver and kidney.
Anti cancer peptide drug conjugates (pd cs) an overviewDoriaFang
Currently, ADC drug research has experienced a pile-up of targets, overlapping indication layouts and similar forms. There is an urgent need for a number of manufacturers to come up with new ideas to solve the existing problems. Some companies have taken an alternative route and laid out peptide-drug conjugate (PDC), which is relatively less competitive.
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfDoriaFang
The more popular targets in ADC drugs include HER2, TROP2, EGFR, CLDN18.2, c-Met, CD19, PSMA, Muc1, BCMA and PDL1. Here we will introduce a new ADC target trophoblast glycoprotein (TPBG).
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfDoriaFang
Summary of Antibody–Oligonucleotide Conjugates(AOCs) in Clinical Trials, including products from Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics and Denali Therapeutics.
Cyclic Peptides Current Status & Future Prospects.pdfDoriaFang
Researchers have made unremitting efforts to optimize peptides in order to improve the bioavailability of peptide drugs. Cyclization of peptides is one of the methods to optimize peptides. Cyclic peptides combine several favorable properties such as good binding affinity, target selectivity and low toxicity that make them an attractive modality for the development of therapeutics.
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfDoriaFang
Alzheimer's disease (AD) is a neurodegenerative disorder marked by cognitive and behavioral impairment. Here we introduce the development of AD drugs (Aducanumab, Lecanemab & Donanemab).
Cleavable Linkers Used In ADC Development.pdfDoriaFang
The linker used in ADC is divided into two types: cleavable linker and non-cleavable linker. This artile mainly introduced the cleavable linkers used in ADC development.
The Role of Four Lipid Components Of LNPs.pdfDoriaFang
LNP consists of four components: ionizable cationic lipids, phospholipids, cholesterol, and PEG lipids. Each component plays a key role in terms of LNP preparations.
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDoriaFang
Enhertu (fam-Trastuzumab deruxtecan-nxki) is a HER2-targeting ADC drug jointly developed by AstraZeneca and Daiichi Sankyo, also known as DS-8201 or T-DXd.
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfDoriaFang
What are the new anti-cancer drugs approved in the first half of the year? The new drugs approved covered a variety of solid tumors and blood tumor types.
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfDoriaFang
Currently, popular targets include CD family, BCMA, HER2, TROP2, Tissue factor, Nectin-4, FRα, EGFR, etc. Here, we briefly introduce ADC targets in solid tumors and hematological tumors.
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfDoriaFang
Scientists are turning their attention to more innovative therapeutic strategies, such as next-generation ADCs, bispecific antibodies and CAR-T cell therapies, etc. as cancer therapy.
Summary of Treatments for Multiple Myeloma.pdfDoriaFang
Currently, there are a variety of drugs available for multiple myeloma, including traditional cytotoxic drugs, immunomodulatory analogs, proteasome inhibitors, antibody-based drugs and CAR T-cell therapy.
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdfDoriaFang
ADCs, PDCs, ISACs, SMDC and Aptamer-Drug Conjugate (ApDC) are the conjugated drugs currently being developed. Here we will introduce the current research progress and challenges of ApDC.
FRα Targeting ADCs for Ovarian cancer.pdfDoriaFang
This article introduces FRα targets and FRα ADCs in clinical trials. There is only one FRα targeting ADC for ovarian cancer - mirvetuximab soravtansine-gynx (Elahere) and a few in clinical trials.
Summary of Approved HER2 ADCs on The Market & in Clinical Trials.pdfDoriaFang
Studies have shown that human epidermal growth factor receptor-2 (HER2) is overexpressed in many tumors and is one of the most common target antigens for ADCs.
LA HUG - Video Testimonials with Chynna Morgan - June 2024Lital Barkan
Have you ever heard that user-generated content or video testimonials can take your brand to the next level? We will explore how you can effectively use video testimonials to leverage and boost your sales, content strategy, and increase your CRM data.🤯
We will dig deeper into:
1. How to capture video testimonials that convert from your audience 🎥
2. How to leverage your testimonials to boost your sales 💲
3. How you can capture more CRM data to understand your audience better through video testimonials. 📊
VAT Registration Outlined In UAE: Benefits and Requirementsuae taxgpt
Vat Registration is a legal obligation for businesses meeting the threshold requirement, helping companies avoid fines and ramifications. Contact now!
https://viralsocialtrends.com/vat-registration-outlined-in-uae/
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
B2B payments are rapidly changing. Find out the 5 key questions you need to be asking yourself to be sure you are mastering B2B payments today. Learn more at www.BlueSnap.com.
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
3.0 Project 2_ Developing My Brand Identity Kit.pptxtanyjahb
A personal brand exploration presentation summarizes an individual's unique qualities and goals, covering strengths, values, passions, and target audience. It helps individuals understand what makes them stand out, their desired image, and how they aim to achieve it.
Recruiting in the Digital Age: A Social Media MasterclassLuanWise
In this masterclass, presented at the Global HR Summit on 5th June 2024, Luan Wise explored the essential features of social media platforms that support talent acquisition, including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok.
Company Valuation webinar series - Tuesday, 4 June 2024FelixPerez547899
This session provided an update as to the latest valuation data in the UK and then delved into a discussion on the upcoming election and the impacts on valuation. We finished, as always with a Q&A
Building Your Employer Brand with Social MediaLuanWise
Presented at The Global HR Summit, 6th June 2024
In this keynote, Luan Wise will provide invaluable insights to elevate your employer brand on social media platforms including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok. You'll learn how compelling content can authentically showcase your company culture, values, and employee experiences to support your talent acquisition and retention objectives. Additionally, you'll understand the power of employee advocacy to amplify reach and engagement – helping to position your organization as an employer of choice in today's competitive talent landscape.
Summary of PROTAC And Other Targeted Protein Degradation Technologies.pdf
1. Biopharma PEG https://www.biochempeg.com
Summary of PROTAC And Other Targeted
Protein Degradation Technologies
Proteolysis targeting chimeras (PROTACs) has come a long way since Crews first
reported in 2001. At present, various degradation technologies based on PROTAC have
been successfully developed for the degradation of kinases, nuclear receptors, epigenetic
proteins, misfolded proteins and RNA. These technologies have greatly broadened the
range of targets and clinical applications for diseases such as cancer, neurodegenerative
diseases and viral diseases. To date, more than 15 PROTAC molecules have entered
clinical trials. In this article, we summarize various targeted degradation strategies
and their respective advantages and disadvantages, hoping to provide guidance
value for the development of targeted protein degradation drugs.
Traditional small molecule inhibitors play a therapeutic role by interfering with protein
function, while protein-targeted degraders play a role by proteasomal degradation of
pathogenic target proteins, resulting in different biological effects, so they have higher
selectivity and efficacy. Several targeted protein degradation strategies have been
reported, among which the most famous is the proteolysis targeting chimera
(PROTAC). In addition, researchers have also developed other types of degraders one
after another, including intracellular click-formed proteolysis-targeting chimeras
(CLIPTACs), photochemical targeting chimera (PHOTAC), semiconducting polymer
nano-PROTAC (SPNpro), floate-PROTAC, antibody-PROTAC conjugate, antibody-based
PROTAC (AbTAC), ribonuclease targeting chimera (RIBOTAC), transcription factor
PROTAC (TF-PROTAC), chaperone-mediated protein degradation (CHAMP), biological
PROTAC (bioPROTAC) and molecular glue, etc.
2. Biopharma PEG https://www.biochempeg.com
Figure 1. Summary of different targeted protein degraders
Targeted Protein Degradation Technologies
1. Proteolysis Targeting Chimeras (PROTACs)
Compared with other targeted protein degradation technologies, PROTAC has been more
widely and deeply studied. It is composed of E3 ubiquitin ligase ligand, protein of interest
(POI) ligand and linker. The formation of the POI-PROTAC-E3 ligase ternary complex can
trigger the ubiquitination and degradation of POI through the ubiquitin-proteasome system.
The concept of PROTAC was first proposed by Craig M. Crews in 2001. Many companies
are involved in PROTAC, including Arvinas, Nurix Therapeutics, Kymera Therapeutics,
C4 Therapeutics, Bristol-Myers Squibb and Novartis. Currently, at least 15 PROTACs
have entered the clinic (Figure 2). Among them, the most advanced ones are the
androgen receptor (AR) degrader ARV-110 for prostate cancer and the estrogen receptor
3. Biopharma PEG https://www.biochempeg.com
(ER) degrader ARV-471 for breast cancer, which have entered phase II clinical trials in
2021.
Figure 2. Summary of PROTACs entering clinical trials
PROTACs have successfully degraded various POIs, including kinases, nuclear receptors,
epigenetic proteins, misfolded proteins, etc. According to statistics, about 3939 PROTACs
have been reported so far, including 981 POI ligands, 74 E3 ligase ligands and 1100
linker chains. A variety of kinase degraders have been developed, such as the
degradation of BCR-Abl, BTK, IRAK4 and EGFR. In addition, nuclear receptor degraders
have been developed, such as the degradation of AR, ER and CRABPs (cellular retinoic
acid binding proteins). There are also many cases of PROTACs targeting epigenetic
proteins, such as: BET, STAT3, Trim24, BRD7/9 IKZF, HDAC6, Sirt2, PCAF/GCN5,
etc. PROTAC technology has also been used to degrade pathogenic misfolded proteins,
such as Tau protein and alpha-synuclein. Studies have shown that PROTACs can cross
the blood-brain barrier for the treatment of neurodegenerative diseases.
In addition to cancer and neurodegenerative diseases, PROTACs can also treat immune
diseases by targeting IRAK4, sirtuin and PCAF/GCN5, as well as viral infections by
targeting HCV NS3/4A protease. For viral infectious diseases, viral RNA replication
requires RNA-dependent RNA/DNA polymerases (RdRp/RdDp), none of which is present
4. Biopharma PEG https://www.biochempeg.com
in the human body, and which possess highly conserved catalytic domains, making them
important targets for a wide range of antiviral drugs. Therefore, PROTACs targeting
RdRp/RdDp will have great clinical potential as pan-viral antivirals.
One of the greatest advantages of PROTAC is that it can degrade "non-drugable" targets
that lack suitable drug-binding sites, such as STAT3 and KRAS. However, due to the high
structural homology of STAT3 with other STAT family members, it is difficult to find highly
selective STAT3 inhibitors. The STAT3 PROTACs SD-36 developed by Wang's group can
selectively degrade STAT3 protein and have excellent anticancer activity in vitro and in
vivo. Another example is the so-called non-drugable target KRAS, mutations of which
have been linked to various cancers. The Crews research group reported in 2020 that the
KRAS-targeting PROTAC molecule LC2 can rapidly and persistently degrade the G12C
mutant KRAS protein. In addition, PROTAC also provides a new way to solve the problem
of cancer drug resistance. For example, the androgen receptor AR-based degrader
ARD-61 developed by Xu's group can overcome the resistance caused by enzalutamide
in vitro and in vivo. In addition, PROTACL18I developed by Yu's group can also effectively
overcome resistance caused by various Bruton's tyrosine kinase (BTK) mutations
produced by ibrutinib. One of the disadvantages of PROTAC is that it can only degrade
intracellular targets, another is poor permeability and oral bioavailability due to its large
molecular weight.
2. Intracellular Click-formed Proteolysis-targeting
Chimeras (CLIPTACs)
PROTACs have limitations due to their poor solubility and poor cell penetration in living
organisms. By utilizing the PROTAC principle and dynamic combinatorial chemistry, the
Heightman team developed a novel PROTAC technology called CLIPTAC (intracellular
click-formed protein hydrolysis-targeted chimeras) to address these issues. CLIPTAC
consists of two fragments, a tetrazine-labeled thalidomide derivative and a
trans-cyclooctene (TCO) -labeled POI ligand. This structure has a lower molecular weight
and better penetration, which can self-assemble and form functional PROTAC molecules
5. Biopharma PEG https://www.biochempeg.com
in the cell by rapid click reaction. Because of the high efficiency and specificity, the
reaction does not cross react with other groups. Two CLIPTACs that degrade BRD4 and
ERK1/2 have been successfully developed (Figure 3). These results provide an advanced
strategy for the design of targeted protein depressors. However, a potentially significant
drawback of CLIPTAC is that the bioorthogonal combination of two click reaction pairs
may occur outside the cell, thus preventing CLIPTAC with high molecular weight and poor
membrane permeability from entering the cell.
Figure 3. Schematic diagram of the mechanism of action of CLIPTAC and the chemical structure of
CLIPTAC based on BRD4 and ERK1/2
3. Photochemical Targeting Chimera (PHOTAC)
Another limitation of PROTAC is that, when administered systemically, it may act in both
tumor and normal cells, leading to off-target effects and non-tumor-specific toxicity.
Photochemically targeted chimeras (PHOTACs), also known as photo-PROTACs or
opto-PROTACs, offer us an excellent solution. PHOTAC is composed of a PROTAC and
a photoremovable group (eg, nitrovaleryloxycarbonyl) or a photoswitchable group (eg,
azobenzene) (Fig. 4). These molecules are inactive in the dark, and upon UV or visible
light irradiation, the photoremovable groups will be separated from PHOTAC, and the
photoswitchable groups will be isomerized, inducing the formation of active PROTAC and
promoting POI degradation. Compared with conventional PROTACs, PHOTACs showed
a more controlled degradation effect in time and space, which may reduce the adverse
toxicity of PROTACs. Various phoTACs have been reported, and many targets such as
6. Biopharma PEG https://www.biochempeg.com
BRD4, FKBP12, IKZF1/3, ALK and BTK have been successfully degraded. However, UV
radiation is difficult to penetrate deep into the body because it induces DNA damage and
is less penetrable. Therefore, the development of PHOTAC with longer wavelength
excitation and higher security and penetration is one of the future development directions.
Figure 4. Mechanism of action and chemical structure of PHOTAC
4. Semiconducting Polymer Nano-PROTAC (SPNpro)
SPNpro is another strategy to address the PROTAC off-target problem. Developed by
Kanyi Pu's group in 2021, it is a ternary complex consisting of a semiconducting polymer
core, a cancer biomarker cleavable peptide, and a traditional PROTAC molecule (Figure
5). On the one hand, SPNpro can produce singlet oxygen under NIR (near infrared)
irradiation to kill tumor cells by inducing a series of cancer immune responses. On the
other hand, SPNpro molecules can be cleaved by cancer biomarkers such as cathepsin B
and release active PROTAC molecules in situ to trigger the degradation of target proteins.
SPNpro shows high cancer tissue specificity and low off-target effects. It provides us with
a new approach for cancer treatment by synergistically combining photochemotherapy
and protein degradation technology. A disadvantage of this approach is the high
molecular weight of SPNpro, resulting in low oral bioavailability.
7. Biopharma PEG https://www.biochempeg.com
Figure 5. The mechanism of action and design ideas of SPNpro
5. Floate-PROTAC
Folate receptor alpha (FOLR1) is highly expressed in various cancer cells such as ovarian,
lung, and breast cancers, but low in normal cells. In order to improve the targeting
efficiency of PROTAC and reduce its off-target effect, the folic acid group is attached to
the traditional PROTAC molecule, so Floate-PROTAC was developed. Floate-PROTAC
can be selectively transported into cancer cells through FOLR1, and the active PROTAC
molecules will be released by cleavage of endogenous hydrolase in cancer cells, thereby
inducing POI ubiquitination and degradation. Jin's group has developed three
Floate-PROTACs (floate-ARV-771, floate-MS432, floate-MS99) targeting BRD, MEK or
ALK (Fig. 6). This strategy can significantly improve the cell selectivity of PROTACs for
selectively degrading proteins in cancer cells. There are currently no in vivo data on
Flot-PROTACs, and their pharmacokinetic and pharmacodynamic properties remain
unknown.
8. Biopharma PEG https://www.biochempeg.com
Figure 6. Mechanism of Floate-PROTAC and chemical structure of Floate-PROTAC
6. Antibody-PROTAC Conjugates and Antibody-Based PROTACs
(AbTACs)
Based on the high selectivity of antibodies, researchers have
developed antibody-PROTAC conjugates and antibody-based PROTAC (FIG. 7) to
address problems such as poor cell and tissue selectivity of PROTACs. For example,
trastuzumab (Herceptin) is a monoclonal antibody used to treat HER2-positive (HER2+)
breast cancer. Trastuzumab-PROTAC conjugate induces degradation of BRD4 protein in
HER2-positive breast cancer cells. Another strategy, called antibody-based PROTAC
(AbTAC), is to combine two antibodies, one linked to an E3 ligase (such as RNF43) and
the other to a targeting protein (such as the immune checkpoint protein PD-L1) (eg AC-1).
Both strategies can overcome the cell and tissue selectivity issues of PROTACs. However,
due to the properties of antibodies, AbTACs need to be administered by injection.
9. Biopharma PEG https://www.biochempeg.com
Figure 7. Mechanism of action of AbTACs
7. Ribonuclease Targeting Chimeras (RIBOTACs)
RNA was previously considered an undruggable drug target due to its small size and lack
of stability. Scientists have recently developed ribonuclease targeting chimeras
(RIBOTACs) by linking RNA-binding molecules to ligands of ribonuclease (RNase L) to
induce RNA degradation (Figure 8). Compared with related inhibitors, RIBOTACs can
degrade RNA in a more efficient and selective manner without binding to the functional
site of RNA. The Disney group developed two RIBOTACs that recruit active RNase L to
oncogenic miRNA-96 or miRNA-210 precursors, respectively, leading to their degradation,
thereby inducing apoptosis in breast cancer cells. In addition, they developed a
RIBOTACs called C5-RIBOTAC that targets the degradation of SARS-CoV-2 FSE
(frameshift element) RNA for SARS-CoV-2 therapy. The disadvantages of RIBOTACs are
10. Biopharma PEG https://www.biochempeg.com
due to their negatively charged structure and large molecular weight (>2000), resulting in
poor cellular uptake and permeability. In addition, RIBOTACs are expected to function in
the cytoplasm since RNase L is predominantly distributed in the cytoplasm.
Figure 8. The mechanism of action of RIBOTAC and the schematic diagram of the structure of
C5-RIBOTAC
8. Transcription Factor-PROTAC (TF-PROTAC)
Transcription factors (TFs) are important targets for cancer therapy. However, the lack of
active sites and allosteric binding pockets makes the development of TFs-based small
molecule inhibitors difficult. Kim's group developed a targeted protein degradation
strategy called TF-PROTAC in 2021 to selectively degrade TFs (FIG. 9). Firstly, based on
the fact that TFs can bind specific DNA-binding sequences or motifs, they modified the
DNA oligonucleotide chain (ODN) that can bind TFs by azide group to obtain ODN
(N3-ODN). After that, N3-ODN binds to bicyclic octylene (BCN) -modified E3 ligase ligand
through click reaction to synthesize target TF-PROTAC, which is then transfected into
cells to induce specific degradation of target TFs. So far they have developed two series
of TF-PROTAC, NF-κB-Protac (dNF-κB) and E2F-PROTAC (dE2F), and shown efficient
degradation of p65 and E2F1 proteins in cells. These results indicate that TF-PROTAC is
an effective strategy to achieve selective degradation of TFs.
11. Biopharma PEG https://www.biochempeg.com
F9 Mechanism of action of TF-PROTAC
9. Chaperone-mediated Protein Degradation (CHAMP)
It has been found that some chaperone proteins such as heat shock protein 90 (HSP90)
are highly activated in tumor cells and can directly interact with various E3 ligases. They
are involved in protein degradation processes to prevent misfolded proteins from
interfering with normal cell function. Based on these functions of chaperones, researchers
have developed a molecular chaperon-mediated protein degradation agent (CHAMP)
consisting of a ligand for POI, a ligand for chaperones, and a linker (FIG. 10). It was found
that CHAMP based on BRD4 exhibited excellent BRD4 degradation and anti-proliferation
effects both in vitro and in vivo. Compared with traditional PROTAC, CHAMP has higher
tumor selectivity.
12. Biopharma PEG https://www.biochempeg.com
Figure 10 Mechanism of action of CHAMP
10. Biological PROTACs (bioPROTACs)
There are more than 600 E3 ligases in the human body, of which less than 2% are used in
PROTAC research. To expand the E3 ligase toolbox of PROTACs, the researchers
developed bioPROTACs, an engineered fusion protein consisting of a target
protein-binding domain and an E3 ubiquitin ligase-binding domain (Figure 11). At present,
researchers have developed two bioPROTACs, Con1-SPOP167-374 and K27-SPOP,
which show degradation effects on proliferating cell nuclear antigens PCNA and KRAS,
respectively. However, since this method relies on genetic coding, it can only be used as a
biological tool.
13. Biopharma PEG https://www.biochempeg.com
Figure 11 Mechanism of action of bioPROTAC and bioPROTAC based on PCNA and KRAS
11.Molecular Glue
Molecular glue is a small molecule compound that can induce PPI (protein-protein
interaction) between E3 ligase and POI, resulting in POI degradation. Unlike PROTACs,
molecular glues have smaller molecular weights and more drug-like properties, making
them a potential cancer treatment strategy. Typical examples of molecular glues include
immunomodulatory drugs (IMiDs), such as thalidomide, which induce the degradation of
casein kinases CK1α, GSPT1 and IKZF 1/3. In addition, arylsulfonamide anticancer drugs,
such as indisulam, can form ternary complexes with DCAF15 and splicing factors RBM23
or RBM39 and induce their degradation. The molecular glue CR8 can also bind
CDK12-cyclin K and the CUL4 adaptor protein DDB1, resulting in the degradation of cyclin
K (Figure 12). However, all molecular glues reported so far have been discovered by
chance, and there is no strategy for rationally designing molecular glue degraders.
14. Biopharma PEG https://www.biochempeg.com
Figure 12. The mechanism of action of molecular glues and the structures of several molecular glues
Conclusion
In addition to the above strategies, there are various other strategies for targeted protein
degradation, such as Trim-Away protein degraders using TRIM21 as E3 ligase and
specific antibodies as POI ligands, lysosome-targeted chimeras (LYTAC),
autophagy-targeted chimeras (AUTAC), and autophagosome-bound compounds
(ATTEC). These technologies provide new ideas for the research and development of
targeted protein degradation drugs, broaden the scope of drug targets, and greatly
promote the development of targeted therapeutic drugs. It has potential application value
in other aspects.
However, there are challenges and opportunities, and each strategy has its limitations.
Some have cell and tissue selectivity problems (such as PROTAC, CLIPTAC, CHAMP
and molecular glue), some have poor cell permeability (such as PHOTAC), and some
have solubility and absorption problems due to special structure or high molecular weight
(such as SPNPRO, Floate -PROTAC, AbTAC, RIBOTAC, TFTAC, bioPROTAC). In
addition, less than 2% of E3 ligases are used for targeted degradation. Therefore, the
discovery of novel E3 ligases that can be used for targeted degradation is one of the
future research directions for PROTAC.
As a leading PEG derivatives supplier, Biopharma PEG is dedicated to the R&D of
PROTAC linker, providing high purity PEG linkers with various reactive groups to
continuously assist customers' project development. We have 3000+ PEG linkers in stock
and can provide multi functionalized PEG derivatives as PROTAC linkers.
15. Biopharma PEG https://www.biochempeg.com
References:
[1]. PROTACs: chimeric molecules that target proteins to the Skp1-Cullin-F boxcomplex for ubiquitination
and degradation, Proc.Natl. Acad. Sci. U. S. A. 2001,98, 8554-8559.
[2].Targeted protein degraders crowd into the clinic, Nat. Rev. Drug Discov. 2021, 20, 247-250.
[3].PROTAC targeted protein degraders: the past is prologue, Nat. Rev. Drug Discov. 2022, 21, 181-200.
[4].Drugging the 'undruggable' cancer targets, Nat. Rev. Cancer 2017, 17, 502-508.
[5].New chemical modalities enabling specific RNA targeting and degradation: application to
SARS-CoV-2 RNA, ACS Cent. Sci., 2020, 6, 1647-1650.
[6].Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4, ACS
Chem. Biol. 2020, 15 ,1306-1312.
Related articles:
[1].12 Types of Targeted Protein Degradation Technologies
[2].Molecular Glues: A New Dawn After PROTAC
[3].PROTACs VS. Traditional Small Molecule Inhibitors
[4].PROTACs and Targeted Protein Degradation
[5].Four Major Trends In The Development of PROTAC